LONDON (Alliance News) - Silence Therapeutics PLC said Monday it had seen an "excellent outcome" in its Phase IIa trial of compound Atu027 in pancreatic cancer.
The primary objective of the trial was to assess the safety and pharmacokinetics of the compound, and the second objective was to evaluate its efficacy including progression free survival.
Atu027 was generally well tolerated, Silence said, with patients in the treatment arm receiving more doses showing no difference in safety events.
There were a total of 23 patients enrolled in the trial separated into two arms, the second of which received 33% more Atu027 in the same period. In both arms of the study, one patient withdrew because of an adverse event.
A preliminary analysts of the study indicates the patients who were exposed to a higher level of Atu027 saw a longer period of progression free survival.
"Even allowing for the small number of patients in the trial, these results show a clear signal which requires further investigation," said Chief Executive Officer Ali Mortazavi in a statement.
"In light of this data, we are reviewing the protocol for the planned Phase Ib head and neck cancer study," Mortazavi added.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.